| Abstrakt: |
The intrasubject and intersubject variabilities for CGS 16617, an angiotensin converting enzyme inhibitor, were evaluated in an open-label, repeat single-dose bioavailability trial. Eight healthy male volunteers each received a 20-mg oral dose of CGS 16617 as an aqueous solution on four separate occasions. Components of variance were evaluated for a mixed-effects statistical model in which subjects were regarded as a random factor. While intersubject variability was statistically significant ( P < 0.05) for all pharmacokinetic variables measured, AUC, C, t, and t, its contribution to the total observed variability was relatively small for AUC, t and t. The proportion of variation due to intrasubject variability was 70, 19, 61, and 72% for AUC, C, t, and t, respectively. Ramifications of the large intrasubject source component of variability as related to bioavailability trials and biological variation are discussed. [ABSTRACT FROM AUTHOR] |
Full text from SpringerLink